EE245 Continuous Avoidance Cost in Biosimilar: A Budget Impact Analysis on the Basis of Clinical Trial Model and RWD in Brazil / LATAM / LMIC
Abstract
Authors
Gabriel Kenzo Tanaka ELIO TANAKA Sr. Sueli Kazue Muramatsu Pereira Hugo Nidahara Romeu Kuabara Rogerio Scarabel Barbosa Freddy Luis Ventura TORREZ Raquel Ferreira Scholz